HK1248522A1 - 调节脂肪代谢障碍群体中的载脂蛋白c-iii(apociii)表达 - Google Patents

调节脂肪代谢障碍群体中的载脂蛋白c-iii(apociii)表达 Download PDF

Info

Publication number
HK1248522A1
HK1248522A1 HK18107740.8A HK18107740A HK1248522A1 HK 1248522 A1 HK1248522 A1 HK 1248522A1 HK 18107740 A HK18107740 A HK 18107740A HK 1248522 A1 HK1248522 A1 HK 1248522A1
Authority
HK
Hong Kong
Prior art keywords
lipodystrophy
apociii
apolipoprotein
populations
modulation
Prior art date
Application number
HK18107740.8A
Other languages
English (en)
Chinese (zh)
Inventor
Digenio Andres
Original Assignee
Ionis Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ionis Pharmaceuticals, Inc. filed Critical Ionis Pharmaceuticals, Inc.
Publication of HK1248522A1 publication Critical patent/HK1248522A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3525—MOE, methoxyethoxy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HK18107740.8A 2015-02-27 2016-02-26 调节脂肪代谢障碍群体中的载脂蛋白c-iii(apociii)表达 HK1248522A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562126439P 2015-02-27 2015-02-27
US62/126,439 2015-02-27
PCT/US2016/019728 WO2016138355A1 (en) 2015-02-27 2016-02-26 Modulation of apolipoprotein c-iii (apociii) expression in lipodystrophy populations

Publications (1)

Publication Number Publication Date
HK1248522A1 true HK1248522A1 (zh) 2018-10-19

Family

ID=56789093

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18107740.8A HK1248522A1 (zh) 2015-02-27 2016-02-26 调节脂肪代谢障碍群体中的载脂蛋白c-iii(apociii)表达

Country Status (13)

Country Link
US (2) US20180245076A1 (enExample)
EP (1) EP3270931A4 (enExample)
JP (1) JP2018511555A (enExample)
KR (1) KR20170122769A (enExample)
CN (1) CN107405358A (enExample)
AU (1) AU2016222548A1 (enExample)
BR (1) BR112017015307A2 (enExample)
CA (1) CA2977971A1 (enExample)
HK (1) HK1248522A1 (enExample)
IL (1) IL253346A0 (enExample)
MX (1) MX2017011009A (enExample)
RU (1) RU2737719C2 (enExample)
WO (1) WO2016138355A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019002818A (es) * 2016-09-12 2019-08-29 Aegerion Pharmaceuticals Inc Metodos para detectar anticuerpos neutralizantes anti-leptina.
AU2017368050A1 (en) 2016-11-29 2019-06-20 Puretech Lyt, Inc. Exosomes for delivery of therapeutic agents
WO2022072244A1 (en) * 2020-10-02 2022-04-07 Ionis Pharmaceuticals, Inc. Methods for reducing apociii expression
JP2024525800A (ja) * 2021-07-16 2024-07-12 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7598227B2 (en) * 2003-04-16 2009-10-06 Isis Pharmaceuticals Inc. Modulation of apolipoprotein C-III expression
PL2670486T3 (pl) * 2011-01-31 2016-08-31 Cadila Healthcare Ltd Leczenie lipodystrofii
UA115309C2 (uk) * 2011-04-27 2017-10-25 Іоніс Фармасьютікалз, Інк. Модуляція експресії аполіпопротеїну ciii (apociii)
DK2956176T3 (en) * 2013-02-14 2018-08-27 Ionis Pharmaceuticals Inc MODULATION OF APOLIPOPROTEIN C-III (APOCIII) EXPRESSION IN LIPOPROTEIN LIPASE DEFICIENT (LPLD) POPULATIONS
US9909124B2 (en) * 2013-06-21 2018-03-06 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating apolipoprotein C-III expression for improving a diabetic profile
US20150045431A1 (en) * 2013-08-06 2015-02-12 Amarin Pharmaceuticals Ireland Limited Methods of treating a cardiovascular disorder in a subject on apo-c3 modulating therapy

Also Published As

Publication number Publication date
RU2017133142A3 (enExample) 2019-08-12
AU2016222548A1 (en) 2017-07-27
US20180245076A1 (en) 2018-08-30
EP3270931A1 (en) 2018-01-24
CN107405358A (zh) 2017-11-28
RU2017133142A (ru) 2019-03-28
EP3270931A4 (en) 2018-10-03
JP2018511555A (ja) 2018-04-26
US20200095581A1 (en) 2020-03-26
MX2017011009A (es) 2017-10-20
KR20170122769A (ko) 2017-11-06
BR112017015307A2 (pt) 2018-01-16
IL253346A0 (en) 2017-09-28
CA2977971A1 (en) 2016-09-01
RU2737719C2 (ru) 2020-12-02
WO2016138355A1 (en) 2016-09-01

Similar Documents

Publication Publication Date Title
WO2015168589A3 (en) Compositions and methods for modulating angiopoietin-like 3 expression
MX383753B (es) Modulación de la expresión similar a la angiopoyetina tipo 3.
IL259133A (en) Jamkaban combinations for the treatment of cardiovascular disease
PH12017501487A1 (en) Methods for treating skin
MX388459B (es) MÉTODOS Y COMPOSICIONES PARA MODULAR LA EXPRESIÓN DE APOLIPOPROTEÍNA (a).
BR112016024186A2 (pt) caixa de coluna vertebral
WO2014179626A3 (en) Compositions and methods for modulating apolipoprotein c-iii expression
HK1244710A1 (zh) 微胶囊化大麻素组合物
PL3358981T3 (pl) But, zwłaszcza but sportowy
PH12019501018A1 (en) Pharmaceutical composition, methods for treating and uses thereof
SG11201705450SA (en) Bacteria-comprising compositions and methods of using the same for treating and/or preventing gastrointestinal, metabolic and/or other diseases
GB201520176D0 (en) Proximal tibial osteotomy
AU2017286811A1 (en) Modulation of gys1 expression
HK1248522A1 (zh) 调节脂肪代谢障碍群体中的载脂蛋白c-iii(apociii)表达
EP3288550C0 (en) STRUCTURALLY IMPROVED SULFUR-CONTAINING FATTY ACIDS FOR USE IN THE TREATMENT OF NONALCOHOLIC FATTY LIVER DISEASE
EP3313763A4 (en) CONTENT INFORMATION ABOUT FLOOR OF AN ELEVATOR
WO2014194053A3 (en) Carbohydrate compounds for nutritional and therapeutic use
Haughney How Sports Illustrated Broke the Jason Collins Story.
EP3170419A4 (en) Shoe having upper and sole
GB201304481D0 (en) Shoe etc lace holes that next to them have numbers 1,2,3 etc from the bottom upwards
Lee Review of the Architecture Competition of Educational Facilities in 2013
IL252971A0 (en) Methods to reduce platelet aggregation and to treat cardiovascular diseases and other medical disorders
CL2015000620A1 (es) Molécula quimérica que permite el reconocimiento y unión de la ldl oxidada del torrente sanguíneo; y uso para tratar niveles altos de colesterol y enfermedades cardiovasculares.
HK1259743A1 (en) Gemcabene combinations for the treatment of cardiovascular disease
GB201502923D0 (en) Citrus spread's lemon flavoured butter